camptothecin has been researched along with mdv 3100 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Figg, WD; Huitema, ADR; Madan, RA; Peer, CJ; Schellens, JHM; Schmidt, KT; Williams, MD; Wroblewski, S | 1 |
| Cordes, LM; Dorlo, TPC; Figg, WD; Huitema, ADR; Madan, RA; Peer, CJ; Pommier, Y; Schmidt, KT; Sciuto, L; Thomas, A; Wroblewski, S | 1 |
2 trial(s) available for camptothecin and mdv 3100
| Article | Year |
|---|---|
Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cyclodextrins; Drug Interactions; Drug Stability; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant | 2020 |
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Camptothecin; Cyclodextrins; Drug Liberation; Female; Half-Life; Humans; Male; Middle Aged; Models, Biological; Neoplasm Staging; Neoplasms; Nitriles; Phenylthiohydantoin; Phthalazines; Piperazines; Topoisomerase I Inhibitors | 2020 |